Pharma News

Treating patients with a rare genetic form of diabetes with therapies designed to treat other more common forms of the disease may do more harm than good, warn researches.

In a major advancement towards an effective treatment of Alzheimer's disease, Swiss scientists have developed an implantable capsule that can turn the patient's immune system against the disease.

With a surge in deaths due to dearth of bone marrow donors, health experts have suggested that patients with blood cancer can prefer haploidentical stem cell transplantation, a new procedure that does not need complete match of donors tissues.

Biopharma major Biocon on Thursday announced that its subsidiary was tying up with a Mexican firm to co-develop generic recombinant human insulin for the US market.

Russian researchers have developed a nanodrug that can identify a brain tumour during the first stage, and can subsequently be used for the diagnosis of other cancer types as well.

[adsense:336x280:8701650588]

High coronary artery calcium score  a measure of arterial ageing puts people at greater risk not only for heart and vascular disease but also for non-cardiovascular diseases such as cancer, chronic kidney disease and lung diseases, says a study.

Patients suffering from chronic myeloid leukemia (CML) a rare form of cancer  can get huge financial benefits if they start using the generic form of drug Gleevec, the patent of which expired in January this year, a study said.

Scientists have developed a new method for harvesting stem cells, which is less invasive and reduces side effects for donors.The new method eliminates the need for the patient to take growth factor injections to increase cell numbers before a transplant.

Baxter International Inc. announced enrollment of the first patient in a US clinical trial for VIVIA, an investigational home haemodialysis (HD) system being developed by Baxter and DEKA Research & Development Corporation.

Novimmune, announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to NI-0501 for the treatment of patients with primary HLH with refractory disease, or with recurrent or progressive disease during conventional therapy. NI-0501 is a fully human, anti-interferon-gamma (IFNγ) monoclonal antibody discovered and developed by Novimmune.